Did You See Kamala Harris' Fourth of July Post? Is the Woman Brain...
On This Independence Day, Re-Watch the Greatest Swimming Relay Race (and Comeback) of...
Vile Weed: Legalization and What Is Left in Its Wake
White House Accuses This Museum of Using Taxpayer Funds to Undermine America
Could a Future President Deport Melania Trump? One Pundit Thinks So.
America 250 Celebrations to Include UFC Fight at White House
A Quick Bible Study Vol. 275: ‘Psalm Summer 2025’ Part 2
Jew or True?
Where to Look for Advice on Iran
Elon Musk Offers an Update on His Plans to Form a Third Party
Another Wildfire Has Hit California and Newsom's Plan Is to Attack Trump
Yikes! Did You See How Biden Celebrated the 4th of July Holiday Weekend...
The Fact-Checkers Once Again Race to Defend Mamdani
It's No Wonder Randi Weingarten Deleted This '4rth of July' Post
Scott Jennings Offers a Telling Reminder on Democrats' 'Big Tent' Amidst Concerns With...
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement